NCT06357988View on ClinicalTrials.gov

Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

February 24, 2016

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphatic System NeoplasmRefractory LymphomaRefractory Malignant Solid NeoplasmRefractory Multiple Myeloma
Interventions
PROCEDURE

Biopsy Procedure

Undergo tumor biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Echocardiography Test

Undergo echocardiography

PROCEDURE

Radionuclide Imaging

Undergo nuclear study

DRUG

Vismodegib

Given PO

Trial Locations (1)

19103

ECOG-ACRIN Cancer Research Group, Philadelphia

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH